Published by Unseen Progress, an independent publisher of caregiver research. Last reviewed 2026-05-10. Part of the stroke caregiver research overview.
Short answer. The risk of a second stroke is highest in the first 90 days after the first (roughly 10–20% in some cohorts of TIA and minor stroke without aggressive prevention) and remains elevated for years afterwards. The 2021 AHA/ASA secondary stroke prevention guidelines (Kleindorfer et al., 2021) describe a multi-component protocol — antiplatelet or anticoagulant therapy, statin therapy, blood pressure control, glycaemic control, lifestyle modification, and screening for and treating sleep apnoea and atrial fibrillation — with each component having its own randomised-trial evidence base. The research view is that secondary prevention is the highest-leverage activity in the chronic phase of stroke care, and that adherence at home is the rate-limiting step.
The Oxford Vascular Study (Coull et al., 2004) and subsequent cohorts placed early recurrence risk after TIA or minor stroke at roughly 10–20% in the first 90 days without aggressive intervention — a number that has driven the entire modern secondary-prevention literature. With guideline-concordant care, the same risk can be reduced substantially.
The CHANCE trial (Wang et al., 2013) and POINT trial (Johnston et al., 2018) established that short-course dual antiplatelet therapy (clopidogrel plus aspirin for 21–90 days, depending on indication) after high-risk TIA or minor ischaemic stroke reduces recurrence relative to aspirin alone.
The SPARCL trial (Amarenco et al., 2006) established that high-intensity statin therapy in stroke survivors without coronary disease reduces recurrent stroke and major cardiovascular events.
The PROGRESS trial (PROGRESS Collaborative Group, 2001) and subsequent analyses established that blood pressure lowering reduces recurrent stroke risk across baseline blood pressure levels — meaning the benefit applies even to survivors who would not have been called hypertensive pre-stroke.
Across these trials and the meta-analytic literature, the consistent finding is that secondary prevention is additive: each well-managed component reduces risk, and the cumulative effect of complete adherence is substantial.
The Kleindorfer et al. (2021) guidelines structure secondary prevention around the following components. Each has its own evidence grade and family-relevant tracking implication.
For non-cardioembolic stroke, antiplatelet therapy (aspirin, clopidogrel, or aspirin-dipyridamole) is first-line. For atrial fibrillation, oral anticoagulation (DOACs in most cases) is first-line. The choice belongs with the treating clinician. The family tracking implication: confirm the prescription, confirm it is filled, confirm it is taken daily. Medication non-adherence is one of the largest preventable recurrence risk factors in the cohort literature.
High-intensity statin therapy is recommended for most ischaemic stroke survivors with LDL targets per the current guidelines (typically LDL <70 mg/dL or even <55 mg/dL in higher-risk populations under the most recent recommendations). The family tracking implication: confirm adherence; ask the clinician about LDL targets and follow-up testing.
The PROGRESS trial benefit was observed across baseline blood pressures, including in survivors not previously diagnosed as hypertensive. The 2021 guidelines target <130/80 mmHg for most stroke survivors. Home blood pressure monitoring is supported as a tool — but only if the technique is correct (rest, cuff placement, multiple readings) and the data goes back to the clinician.
Diabetes is a known stroke risk factor; tight glycaemic control reduces microvascular complications and contributes to overall vascular risk. The 2021 guidelines support individualised A1c targets, generally <7%.
A meaningful fraction of "cryptogenic" strokes are actually due to undetected paroxysmal AF. Extended cardiac monitoring (loop recorders, multi-week patch monitors) has high yield in suitably selected survivors and changes management from antiplatelet to anticoagulant.
Obstructive sleep apnoea is over-represented in stroke survivors and is associated with elevated recurrence risk. Screening is supported; treatment of significant OSA with CPAP improves outcomes and is recommended when warranted.
The lifestyle components in the guidelines are not afterthoughts; they have measurable effect sizes. Smoking cessation has among the largest absolute risk reductions of any intervention in stroke survivors. Physical activity, Mediterranean-style dietary patterns, and weight management each carry independent evidence in the secondary prevention context.
For survivors with significant symptomatic carotid stenosis, revascularisation (endarterectomy or stenting) is a separate decision pathway with its own evidence base.
The research consensus is that adherence drops sharply in the first 6–12 months after stroke if not actively monitored. Families that protect adherence are operating on the single highest-leverage variable in the secondary prevention picture. The trackable inputs are:
Any new acute focal neurological symptom: facial droop, arm weakness, speech difficulty, sudden severe headache, sudden vision change, sudden loss of balance, sudden confusion. The BE-FAST framework adds Balance and Eyes to the classic FAST mnemonic. Stroke care is time-critical. Family hesitation is a known cause of delayed presentation.
---
Unseen Progress publishes long-form caregiver research and builds research-backed daily trackers for the families covered. See the full stroke caregiver research overview for the complete framework.